Dr. Sepehr Nowfar, MD

Dr. Nowfar practices at Centinela Valley Endoscopy Center - HOPD in Inglewood, California.

Dr. Nowfar's NPI, 1124174560, was assigned on January 26, 2007. Dr. Nowfar graduated from Tulane School of Medicine in 2005. Dr. Nowfar holds California license A97699.

Dr. Nowfar's primary practice is Centinela Valley Endoscopy Center - HOPD, at 575 E Hardy St, Inglewood, CA 90301.

Dr. Nowfar's primary practice is Centinela Valley Endoscopy Center - HOPD in Inglewood, California. Dr. Nowfar is also affiliated with UCI Health - Orange. The medical group on file is Unio Specialty Care, Urology, Encinitas (formerly Genesis Healthcare Partners). Dmand AI also links Dr. Nowfar to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nowfar practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Nowfar's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Nowfar is board certified in urology by the American Board of Urology. Dr. Nowfar is licensed in California.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and pelvic prolapse among the conditions Dr. Nowfar treats.

CMS data shows 3,845 Medicare services from Dr. Nowfar across 26 procedure codes in 2024, for 570 Medicare patients. Medicare paid $219,526 for them. Every service was in an office.

CMS counts 570 Medicare patients who saw Dr. Nowfar in 2024. The largest group is 65 to 74, with 242 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nowfar's median patient age at 71, with 26% women.

In 2024, Dr. Nowfar wrote 1,449 Medicare Part D claims for 427 patients. 91% of them were for generic drugs. CMS names the drug for 1,288 of them, across 23 drugs with 11 or more claims each, at $534,721 in total drug cost. In 2023, CMS named 1,232 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Nowfar for performance year 2024, reported as part of a group. Dr. Nowfar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nowfar as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Nowfar, published from 2005 to 2012. The most frequent topics are Communication, Diabetes Mellitus and Internet. Dr. Nowfar's most frequent co-authors are Douglas Slakey, MD and Roger Lu Sur, MD.

CMS Open Payments shows 530 general payments to Dr. Nowfar from 67 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Teleflex LLC paid the most, $9,099.

Dmand AI lists 1 award for Dr. Nowfar, most recently CMS Stage 1 EHR in 2012.

Dr. Nowfar graduated from Tulane School of Medicine in 2005.

Dr. Nowfar is in network with 16 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.